Machine Learning Tool Can Predict Cancer in Patients With Multiple Lung Nodules
Tool outperformed preexisting mathematical models and a previously established artificial intelligence tool
Progress Against Cancer
Tool outperformed preexisting mathematical models and a previously established artificial intelligence tool
To learn more about cancer prevention and risk reduction, we talked to Raymond N. DuBois, MD, PhD, FAACR, co-editor in chief of the American Association for Cancer Research (AACR)’s journal Cancer Prevention Research and...
The FDA approved the immune checkpoint inhibitor, cemiplimab-rwlc, for certain patients with locally advanced or metastatic basal cell carcinoma
Organizations call to prioritize cancer patients for COVID-19 vaccination, researchers analyze rates of “low-value” breast surgeries, and UCLA cancer survivors write letters to patients undergoing treatment.
The FDA approved a CAR T-cell therapy – a class of cancer immunotherapy – to treat certain patients with large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
The FDA granted accelerated approval to a molecularly targeted therapeutic for certain patients with marginal zone lymphoma or follicular lymphoma.
On December 31, 2019, the first cases of “a pneumonia of unknown cause”—now known to be COVID-19—were reported in China, and the initial confirmed case in the United States was reported just weeks later. Less than one year after this novel disease was...
The first AACR virtual meeting of 2021, held Jan. 11-12, focused on the tumor microenvironment, the complex framework of immune cells, blood vessels, fibroblasts, and other cell types that surround a tumor and can...
The FDA granted accelerated approval to a new oral targeted therapeutic to treat certain adult patients with the most common form of lung cancer.
An FDA committee votes to recommend holding off on approval of an immunotherapy for early-stage triple-negative breast cancer, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More